2024 Q2 Form 10-Q Financial Statement
#000143774924017062 Filed on May 15, 2024
Income Statement
Concept | 2024 Q2 | 2024 Q1 |
---|---|---|
Revenue | $0.00 | $0.00 |
YoY Change | ||
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | $1.462M | $1.316M |
YoY Change | 63.17% | 33.74% |
% of Gross Profit | ||
Research & Development | $1.361M | $2.392M |
YoY Change | -55.04% | 96.87% |
% of Gross Profit | ||
Depreciation & Amortization | ||
YoY Change | ||
% of Gross Profit | ||
Operating Expenses | $1.361M | $2.392M |
YoY Change | -55.04% | 96.87% |
Operating Profit | -$2.823M | -$3.708M |
YoY Change | -28.04% | -42.32% |
Interest Expense | $52.00K | $49.00K |
YoY Change | -8.77% | -104.18% |
% of Operating Profit | ||
Other Income/Expense, Net | $122.0K | -$641.0K |
YoY Change | -231.18% | -45.35% |
Pretax Income | -$2.701M | -$4.349M |
YoY Change | -32.74% | -42.79% |
Income Tax | ||
% Of Pretax Income | ||
Net Earnings | -$2.692M | -$4.349M |
YoY Change | -32.97% | -42.79% |
Net Earnings / Revenue | ||
Basic Earnings Per Share | -$6.43 | -$15.40 |
Diluted Earnings Per Share | -$2.41 | -$7.72 |
COMMON SHARES | ||
Basic Shares Outstanding | 941.0K | 44.26M |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2024 Q2 | 2024 Q1 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $4.919M | $3.194M |
YoY Change | 213.11% | -61.22% |
Cash & Equivalents | $4.919M | $3.194M |
Short-Term Investments | ||
Other Short-Term Assets | $69.00K | $116.0K |
YoY Change | 0.0% | -41.41% |
Inventory | ||
Prepaid Expenses | ||
Receivables | ||
Other Receivables | ||
Total Short-Term Assets | $4.988M | $3.310M |
YoY Change | 199.4% | -60.81% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | ||
YoY Change | ||
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | ||
YoY Change | ||
Total Long-Term Assets | $0.00 | $0.00 |
YoY Change | ||
TOTAL ASSETS | ||
Total Short-Term Assets | $4.988M | $3.310M |
Total Long-Term Assets | $0.00 | $0.00 |
Total Assets | $4.988M | $3.310M |
YoY Change | 199.4% | -60.81% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $592.0K | $662.0K |
YoY Change | 32.74% | 100.61% |
Accrued Expenses | $522.0K | $337.0K |
YoY Change | -65.06% | -92.6% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $1.161M | $1.412M |
YoY Change | -85.14% | -86.68% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Other Long-Term Liabilities | ||
YoY Change | ||
Total Long-Term Liabilities | $0.00 | $0.00 |
YoY Change | ||
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $1.161M | $1.412M |
Total Long-Term Liabilities | $0.00 | $0.00 |
Total Liabilities | $1.161M | $1.412M |
YoY Change | -85.14% | -86.68% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$98.00M | -$95.30M |
YoY Change | 6.41% | 8.17% |
Common Stock | $0.00 | $0.00 |
YoY Change | -100.0% | -100.0% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $4.764M | $2.836M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $4.988M | $3.310M |
YoY Change | 199.4% | -60.81% |
Cashflow Statement
Concept | 2024 Q2 | 2024 Q1 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$2.692M | -$4.349M |
YoY Change | -32.97% | -42.79% |
Depreciation, Depletion And Amortization | ||
YoY Change | ||
Cash From Operating Activities | -$2.253M | -$3.120M |
YoY Change | -51.7% | 98.35% |
INVESTING ACTIVITIES | ||
Capital Expenditures | ||
YoY Change | ||
Acquisitions | ||
YoY Change | ||
Other Investing Activities | $0.00 | |
YoY Change | -100.0% | |
Cash From Investing Activities | $0.00 | |
YoY Change | -100.0% | |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 3.978M | $4.531M |
YoY Change | 46.11% | |
NET CHANGE | ||
Cash From Operating Activities | -2.253M | -$3.120M |
Cash From Investing Activities | 0.000 | |
Cash From Financing Activities | 3.978M | $4.531M |
Net Change In Cash | 1.725M | $1.411M |
YoY Change | -125.88% | -7.66% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$2.253M | -$3.120M |
Capital Expenditures | ||
Free Cash Flow | ||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2024Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2024Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2024Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2024Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | |
CY2024Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2024Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2024Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | |
CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
250000 | |
CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
250000 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
250000 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
250000 | |
CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
75000000 | |
CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
590188 | |
CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
590188 | |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
341324 | |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
341324 | |
CY2024Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | pure |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | |
CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
CY2024Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2024Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2024Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-03-31 | |
CY2024Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2024Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2024Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
47-4113275 | |
CY2024Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
1111 Kane Concourse, Suite 301 | |
CY2024Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Bay Harbor Islands | |
CY2024Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
FL | |
CY2024Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
33154 | |
CY2024Q1 | dei |
City Area Code
CityAreaCode
|
781 | |
CY2024Q1 | dei |
Security12b Title
Security12bTitle
|
Common Stock | |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
1196000 | usd |
CY2024Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2024Q1 | dei |
Trading Symbol
TradingSymbol
|
ATXI | |
CY2024Q1 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2024Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2024Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2024Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2024Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2024Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2024Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2024Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
940986 | |
CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
3194000 | usd |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1783000 | usd |
CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
116000 | usd |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
67000 | usd |
CY2024Q1 | us-gaap |
Assets
Assets
|
3310000 | usd |
CY2023Q4 | us-gaap |
Assets
Assets
|
1850000 | usd |
CY2024Q1 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
413000 | usd |
CY2023Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
586000 | usd |
CY2024Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1412000 | usd |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1196000 | usd |
CY2024Q1 | us-gaap |
Liabilities
Liabilities
|
1412000 | usd |
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
0 | usd |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | usd |
CY2024Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
98104000 | usd |
CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
92507000 | usd |
CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-95268000 | usd |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-90928000 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2836000 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1582000 | usd |
CY2024Q1 | us-gaap |
Minority Interest
MinorityInterest
|
-938000 | usd |
CY2023Q4 | us-gaap |
Minority Interest
MinorityInterest
|
-928000 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
1898000 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
654000 | usd |
CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
3310000 | usd |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1850000 | usd |
CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2392000 | usd |
CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1215000 | usd |
CY2024Q1 | atxi |
Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
|
0 | usd |
CY2023Q1 | atxi |
Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
|
4230000 | usd |
CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1316000 | usd |
CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
984000 | usd |
CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3708000 | usd |
CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6429000 | usd |
CY2024Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
49000 | usd |
CY2023Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
37000 | usd |
CY2024Q1 | atxi |
Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
|
-0 | usd |
CY2023Q1 | atxi |
Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
|
332000 | usd |
CY2024Q1 | atxi |
Loss On Warrant Liabilities Classified As Inducement Fee
LossOnWarrantLiabilitiesClassifiedAsInducementFee
|
574000 | usd |
CY2023Q1 | atxi |
Loss On Warrant Liabilities Classified As Inducement Fee
LossOnWarrantLiabilitiesClassifiedAsInducementFee
|
-0 | usd |
CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
116000 | usd |
CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
878000 | usd |
CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-641000 | usd |
CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1173000 | usd |
CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-4349000 | usd |
CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-7602000 | usd |
CY2024Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-9000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-66000 | usd |
CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-4340000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-7536000 | usd |
CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-15.4 | |
CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-101.57 | |
CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
562031 | |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
74198 | |
CY2023Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
654000 | usd |
CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
191000 | usd |
CY2024Q1 | atxi |
Common Shares Issuable Founders Agreement
CommonSharesIssuableFoundersAgreement
|
-363000 | usd |
CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
371000 | usd |
CY2024Q1 | atxi |
Adjustments To Apic Loss On Settlement Of Common Stock Warrant Liabilities
AdjustmentsToApicLossOnSettlementOfCommonStockWarrantLiabilities
|
574000 | usd |
CY2024Q1 | atxi |
Stock Issued During Period Value Exercise0f Warrants
StockIssuedDuringPeriodValueExercise0fWarrants
|
5262000 | usd |
CY2024Q1 | atxi |
Adjustments To Additional Paid In Capital Warrant Inducement Offering Costs
AdjustmentsToAdditionalPaidInCapitalWarrantInducementOfferingCosts
|
442000 | usd |
CY2024Q1 | atxi |
Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
|
0 | usd |
CY2024Q1 | atxi |
Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance
AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance
|
0 | usd |
CY2024Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-9000 | usd |
CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-4340000 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
1898000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
3266000 | usd |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
11000 | usd |
CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
72000 | usd |
CY2023Q1 | atxi |
Shares And Warrants Issued During Period Value
SharesAndWarrantsIssuedDuringPeriodValue
|
865000 | usd |
CY2023Q1 | atxi |
Stock Issued During Period Value License Expense
StockIssuedDuringPeriodValueLicenseExpense
|
1231000 | usd |
CY2023Q1 | atxi |
Stock Issued During Period Value Exercise0f Warrants
StockIssuedDuringPeriodValueExercise0fWarrants
|
0 | usd |
CY2023Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-66000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-7536000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-2157000 | usd |
CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-4349000 | usd |
CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-7602000 | usd |
CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
191000 | usd |
CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11000 | usd |
CY2024Q1 | atxi |
Loss On Warrant Liabilities Classified As Inducement Fee
LossOnWarrantLiabilitiesClassifiedAsInducementFee
|
574000 | usd |
CY2023Q1 | atxi |
Loss On Warrant Liabilities Classified As Inducement Fee
LossOnWarrantLiabilitiesClassifiedAsInducementFee
|
0 | usd |
CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
116000 | usd |
CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
878000 | usd |
CY2024Q1 | atxi |
Issuance Of Stock For Licenses Acquired
IssuanceOfStockForLicensesAcquired
|
0 | usd |
CY2023Q1 | atxi |
Issuance Of Stock For Licenses Acquired
IssuanceOfStockForLicensesAcquired
|
1230000 | usd |
CY2024Q1 | atxi |
Common Stock Issued To Fortress Value
CommonStockIssuedToFortressValue
|
371000 | usd |
CY2023Q1 | atxi |
Common Stock Issued To Fortress Value
CommonStockIssuedToFortressValue
|
72000 | usd |
CY2024Q1 | atxi |
Issuance Of Stock Under Founders Agreement
IssuanceOfStockUnderFoundersAgreement
|
-363000 | usd |
CY2023Q1 | atxi |
Issuance Of Stock Under Founders Agreement
IssuanceOfStockUnderFoundersAgreement
|
0 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Due From Other Related Parties Current
IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
|
-0 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Due From Other Related Parties Current
IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
|
13000 | usd |
CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
49000 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
61000 | usd |
CY2024Q1 | atxi |
Increase Decrease In Accrued Licenses Acquired
IncreaseDecreaseInAccruedLicensesAcquired
|
0 | usd |
CY2023Q1 | atxi |
Increase Decrease In Accrued Licenses Acquired
IncreaseDecreaseInAccruedLicensesAcquired
|
3000000 | usd |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3120000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1573000 | usd |
CY2024Q1 | atxi |
Issuance Of Common Stock Prefund Warrants And Warrants
IssuanceOfCommonStockPrefundWarrantsAndWarrants
|
0 | usd |
CY2023Q1 | atxi |
Issuance Of Common Stock Prefund Warrants And Warrants
IssuanceOfCommonStockPrefundWarrantsAndWarrants
|
3101000 | usd |
CY2024Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
4973000 | usd |
CY2023Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
0 | usd |
CY2024Q1 | atxi |
Payments Of Warrants Exercise Transaction Costs
PaymentsOfWarrantsExerciseTransactionCosts
|
442000 | usd |
CY2023Q1 | atxi |
Payments Of Warrants Exercise Transaction Costs
PaymentsOfWarrantsExerciseTransactionCosts
|
-0 | usd |
CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4531000 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3101000 | usd |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
1411000 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
1528000 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
1783000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
6708000 | usd |
CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
3194000 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
8236000 | usd |
CY2024Q1 | atxi |
Unpaid Research And Development Licenses Acquired
UnpaidResearchAndDevelopmentLicensesAcquired
|
0 | usd |
CY2023Q1 | atxi |
Unpaid Research And Development Licenses Acquired
UnpaidResearchAndDevelopmentLicensesAcquired
|
3000000 | usd |
CY2024Q1 | us-gaap |
Stock Issued1
StockIssued1
|
371000 | usd |
CY2023Q1 | us-gaap |
Stock Issued1
StockIssued1
|
0 | usd |
CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
75000000 | |
CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0 | |
CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-95300000 | usd |
CY2024Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | pure |
CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
1311 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
196.21 | |
CY2024Q1 | atxi |
Deemed Dividends
DeemedDividends
|
4300000 | usd |
CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
768864 | |
CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
96007 | |
CY2019Q4 | atxi |
Contractual Obligation Development Expense
ContractualObligationDevelopmentExpense
|
81500000 | usd |
CY2019Q4 | atxi |
Contractual Obligation Commercial Expense
ContractualObligationCommercialExpense
|
151000000 | usd |
CY2016Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
75000000 | |
CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
0 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
|
-0 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
|
0 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
283 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
85.5 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
1028 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
226.69 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
22474000 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
85.5 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | usd |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0 | |
CY2024Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
-0 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
-0 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
0 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
-0 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
0 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
22474000 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
85.5 | |
CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y2M12D | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
16304000 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
85.5 | |
CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P9Y2M12D | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
0 | usd |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
6170000 | |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
85.5 | |
CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P9Y2M12D | |
CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
0 | usd |
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | |
CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
191000 | usd |
CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
11000 | usd |
CY2023Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
524601 | |
CY2023Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
32.42 | |
CY2023 | atxi |
Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
|
0 | usd |
CY2024Q1 | atxi |
Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
|
441076 | |
CY2024Q1 | atxi |
Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights
|
22.55 | |
CY2024Q1 | atxi |
Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
|
220538 | |
CY2024Q1 | atxi |
Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights
|
22.55 | |
CY2024Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
745139 | |
CY2024Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
29.5 | |
CY2024Q1 | atxi |
Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
|
0 | usd |